Consolidated Portfolio Review Corp Has $949,000 Stock Position in Eli Lilly and Company (NYSE:LLY)

Consolidated Portfolio Review Corp lessened its holdings in Eli Lilly and Company (NYSE:LLY) by 80.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,071 shares of the company’s stock after selling 4,530 shares during the quarter. Consolidated Portfolio Review Corp’s holdings in Eli Lilly and Company were worth $949,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Trilogy Capital Inc. bought a new stake in shares of Eli Lilly and Company during the first quarter worth $308,000. ADE LLC bought a new stake in Eli Lilly and Company during the 1st quarter worth $201,000. Financial Partners Group LLC acquired a new position in Eli Lilly and Company in the 1st quarter worth about $232,000. Mayfair Advisory Group LLC raised its position in Eli Lilly and Company by 5.7% in the first quarter. Mayfair Advisory Group LLC now owns 1,489 shares of the company’s stock valued at $1,158,000 after purchasing an additional 80 shares during the last quarter. Finally, Koss Olinger Consulting LLC acquired a new stake in shares of Eli Lilly and Company during the first quarter valued at about $5,154,000. Institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the topic of several recent research reports. Citigroup lifted their target price on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Friday. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $1,025.00 price target on shares of Eli Lilly and Company in a report on Thursday, October 3rd. BMO Capital Markets increased their price objective on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $885.00 target price on shares of Eli Lilly and Company in a report on Monday, September 16th. Finally, Guggenheim upped their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $1,013.41.

Eli Lilly and Company Stock Up 0.2 %

Eli Lilly and Company stock opened at $892.70 on Monday. The company has a market capitalization of $848.43 billion, a PE ratio of 131.47, a PEG ratio of 3.24 and a beta of 0.42. Eli Lilly and Company has a 12-month low of $547.61 and a 12-month high of $972.53. The firm’s fifty day moving average is $919.74 and its 200 day moving average is $863.20. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating the consensus estimate of $2.64 by $1.28. The firm had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. As a group, sell-side analysts predict that Eli Lilly and Company will post 14.05 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.